Methods of using IL-1β compounds to treat familial mediterranean fever (FMF)

Patent metadata

Field	Value
Publication number	US-9649377-B2
Application number	US-201514810556-A
Country	US
Kind code	B2
Filing date	Jul 28, 2015
Priority date	Oct 26, 2005
Publication date	May 16, 2017
Grant date	May 16, 2017

Abstract

This invention relates to methods employing IL-1β-ligand/IL-1 receptor disrupting compounds such as IL-1β antibodies or IL-1 receptor antibodies, in the treatment and/or prevention of Familial Mediterranean Fever (FMF), in mammals, particularly humans.

First claim

What is claimed is:

1. A method of treating Familial Mediterranean Fever (FMF), comprising administering to a patient in need thereof an effective amount of an IL-1beta antibody comprising:
a) an immunoglobulin heavy chain variable domain (V H ) comprising the amino acid sequence set forth as SEQ ID NO:1;
b) an immunoglobulin light chain variable domain (V L ) comprising the amino acid sequence set forth as SEQ ID NO:2;
c) an immunoglobulin V H comprising the amino acid sequence set forth as SEQ ID NO: 1 and an immunoglobulin V L comprising the amino acid sequence set forth as SEQ ID NO: 2; or
d) the three CDRs of the V H as set forth as SEQ ID NO:1 and the three CDRs of the V L as set forth as SEQ ID NO:2.

2. The method according to claim 1 , wherein the IL-1beta antibody comprises
a) an immunoglobulin V H comprising the amino acid sequence set forth as SEQ ID NO: 1 and an immunoglobulin V L comprising the amino acid sequence set forth as SEQ ID NO: 2; or
b) the three CDRs of the V H as set forth as SEQ ID NO:1 and the three CDRs of the V L as set forth as SEQ ID NO:2.

3. The method according to claim 2 , wherein the three CDRs of SEQ ID NO:1 comprise the amino acid sequences set forth as SEQ ID NOs:3-5, and wherein the three CDRs of SEQ ID NO:2 comprise the amino acid sequences set forth as SEQ ID NOs:6-8.

4. The method according to claim 2 , wherein the IL-1beta antibody comprises an antigen binding site comprising:
at least one immunoglobulin V H which comprises in sequence hypervariable regions CDR1, CDR2 and CDR3, said CDR1 having the amino acid sequence Val-Tyr-Gly-Met-Asn (SEQ ID NO: 3), said CDR2 having the amino acid sequence Ile-Ile-Trp-Tyr-Asp-Gly-Asp-Asn-Gln-Tyr-Tyr-Ala-Asp-Ser-Val-Lys-Gly (SEQ ID NO: 4), and said CDR3 having the amino acid sequence Asp-Leu-Arg-Thr-Gly-Pro (SEQ ID NO: 5); and
at least one immunoglobulin V L which comprises in sequence hypervariable regions CDR1′, CDR2′ and CDR3′, said CDR1′ having the amino acid sequence Arg-Ala-Ser-Gln-Ser-Ile-Gly-Ser-Ser-Leu-His (SEQ ID NO: 6), said CDR2′ having the amino acid sequence Ala-Ser-Gln-Ser-Phe-Ser (SEQ ID NO: 7), and said CDR3′ having the amino acid sequence His-Gln-Ser-Ser-Ser-Leu-Pro (SEQ ID NO: 8).

5. The method of claim 4 , wherein the IL-1beta antibody is a human antibody.

6. The method of claim 5 , wherein the IL-1beta antibody is administered once every week or less frequently.

7. The method of claim 6 , wherein the IL-1beta antibody is administered to the patient subcutaneously.

8. The method of claim 5 , wherein the IL-1beta antibody is administered once every month or less frequently.

9. The method of claim 5 , wherein the IL-1beta antibody is administered once every two months or less frequently.

10. The method of claim 5 , wherein the IL-1beta antibody is administered once every three months or less frequently.

11. The method of claim 5 , wherein the IL-1beta antibody is administered once every four months or less frequently.

Assignees

• Lowe Philip
• Gram Hermann
• Jung Thomas
• Wright Timothy
• Mundel Trevor
• Novartis Ag

Inventors

• Lowe Philip
• Gram Hermann
• Jung Thomas
• Wright Timothy
• Mundel Trevor

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title